Alpha Mark Advisors, LLC Amgen Inc Transaction History

Alpha Mark Advisors, LLC

$284 Million
Q1 2024

A detailed history of Alpha Mark Advisors, LLC transactions in Amgen Inc stock. As of the latest transaction made, Alpha Mark Advisors, LLC holds 1,075 shares of AMGN stock, worth $334,819. This represents 0.11% of its overall portfolio holdings.

Number of Shares

1,075

Previous 1,073 0.19%

Holding current value

$334,819

Previous $309,000 0.97%

% of portfolio

0.11%

Previous 0.12%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 18, 2024	BUY	$268.87 - $324.56 $537 - $649	2 Added 0.19%	1,075 $306,000
Q4 2023 Jan 19, 2024	BUY	$255.7 - $288.46 $7,159 - $8,076	28 Added 2.68%	1,073 $309,000
Q3 2023 Oct 31, 2023	SELL	$218.65 - $271.46 $17,054 - $21,173	-78 Reduced 6.95%	1,045 $281,000
Q2 2023 Jul 28, 2023	BUY	$214.27 - $253.37 $428 - $506	2 Added 0.18%	1,123 $249,000
Q1 2023 May 04, 2023	BUY	$225.79 - $275.2 $677 - $825	3 Added 0.27%	1,121 $271,000

Q4 2022 Feb 06, 2023	BUY	$229.03 - $291.01 $229 - $291	1 Added 0.09%	1,118 $294,000
Q3 2022 Nov 14, 2022	BUY	$224.46 - $253.15 $8,978 - $10,126	40 Added 3.71%	1,117 $252,000
Q2 2022 Aug 11, 2022	BUY	$230.71 - $256.74 $461 - $513	2 Added 0.19%	1,077 $262,000
Q1 2022 May 02, 2022	BUY	$219.27 - $242.57 $438 - $485	2 Added 0.19%	1,075 $260,000
Q4 2021 Feb 09, 2022	SELL	$198.88 - $227.6 $26,252 - $30,043	-132 Reduced 10.95%	1,073 $241,000
Q3 2021 Nov 05, 2021	SELL	$212.27 - $248.7 $1,698 - $1,989	-8 Reduced 0.66%	1,205 $256,000
Q2 2021 Aug 06, 2021	BUY	$233.58 - $259.14 $467 - $518	2 Added 0.17%	1,213 $296,000
Q1 2021 Apr 29, 2021	BUY	$221.91 - $258.6 $443 - $517	2 Added 0.17%	1,211 $301,000
Q4 2020 Feb 01, 2021	BUY	$216.38 - $257.67 $2,380 - $2,834	11 Added 0.92%	1,209 $277,000
Q3 2020 Nov 06, 2020	SELL	$234.65 - $260.95 $938 - $1,043	-4 Reduced 0.33%	1,198 $304,000
Q2 2020 Aug 10, 2020	BUY	$197.81 - $242.74 $5,934 - $7,282	30 Added 2.56%	1,202 $283,000
Q1 2020 Apr 24, 2020	BUY	$182.24 - $241.7 $9,476 - $12,568	52 Added 4.64%	1,172 $238,000
Q4 2019 Feb 07, 2020	BUY	$189.21 - $243.2 $9,460 - $12,160	50 Added 4.67%	1,120 $270,000
Q3 2019 Nov 01, 2019	SELL	$174.11 - $208.62 $17,411 - $20,862	-100 Reduced 8.55%	1,070 $207,000
Q2 2019 Aug 02, 2019	SELL	$166.7 - $195.41 $42,508 - $49,829	-255 Reduced 17.89%	1,170 $216,000
Q1 2019 May 09, 2019	SELL	$180.87 - $203.88 $4.17 Million - $4.7 Million	-23,077 Reduced 94.18%	1,425 $271,000
Q4 2018 Feb 06, 2019	SELL	$178.4 - $208.25 $594,072 - $693,472	-3,330 Reduced 11.96%	24,502 $4.77 Million
Q3 2018 Nov 05, 2018	SELL	$185.29 - $208.89 $76,339 - $86,062	-412 Reduced 1.46%	27,832 $5.77 Million
Q2 2018 Aug 03, 2018	BUY	$166.05 - $186.51 $44,999 - $50,544	271 Added 0.97%	28,244 $5.21 Million
Q1 2018 May 09, 2018	SELL	$169.43 - $198.0 $277,526 - $324,324	-1,638 Reduced 5.53%	27,973 $4.77 Million
Q4 2017 Feb 09, 2018	BUY	$168.79 - $188.59 $15,359 - $17,161	91 Added 0.31%	29,611 $5.15 Million
Q3 2017 Nov 02, 2017	BUY	$167.29 - $191.0 $4.94 Million - $5.64 Million	29,520	29,520 $5.5 Million

Others Institutions Holding AMGN

# of Institutions

2,934

Shares Held

401M

Call Options Held

6.59M

Put Options Held

6.6M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $167B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alpha Mark Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alpha Mark Advisors, LLC with notifications on news.

Account

Alpha Mark Advisors, LLC Amgen Inc Transaction History